Scarica l'app Stockscreener
16.12
0.19%
0.03
Dopo l'orario di chiusura:
16.10
-0.02
-0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$16.09
Aprire:
$15.78
Volume 24 ore:
2.62M
Relative Volume:
1.00
Capitalizzazione di mercato:
$12.00B
Reddito:
$220.00K
Utile/perdita netta:
$-921.61M
Rapporto P/E:
-12.98
EPS:
-1.2418
Flusso di cassa netto:
$-274.60M
1 W Prestazione:
+2.81%
1M Prestazione:
-2.24%
6M Prestazione:
-38.47%
1 anno Prestazione:
-14.44%
Intervallo 1D:
$15.50
$16.80
Intervallo di 1 settimana:
$15.39
$16.80
Portata 52W:
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
16.12 | 11.98B | 220.00K | -921.61M | -274.60M | -1.2418 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.43 | 122.19B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.19 | 83.21B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.28 | 51.13B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.85 | 43.68B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
369.00 | 41.01B | 4.98B | 69.60M | 525.67M | 0.5198 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: - GuruFocus
Earnings Call Summary | Summit Therapeutics(SMMT.US) Q4 2025 Earnings Conference - 富途牛牛
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus - TradingView
Assessing Summit Therapeutics (SMMT) Valuation After Recent Share Price Swings - simplywall.st
Summit Therapeutics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
SMMT: Analyst Lowers Price Target to $30, Maintains Buy Rating | SMMT Stock News - GuruFocus
Summit Therapeutics (SMMT) Q4 Earnings Miss Expectations - GuruFocus
Summit Therapeutics (SMMT) Set for Potential Upside Ahead of Key Data Release - GuruFocus
Summit Therapeutics (SMMT) Highlights Progress in Cancer Drug De - GuruFocus
Summit Therapeutics (SMMT) Is Up 7.6% After Steep Losses And New US$102 Million Shelf RegistrationHas The Bull Case Changed? - Yahoo Finance
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus
Earnings call transcript: Summit Therapeutics Q4 2025 reports significant EPS miss - Investing.com Nigeria
Summit Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Summit Therapeutics (SMMT) Updates on HARMONi-3 Trial Progress - GuruFocus
Summit Therapeutics falls on earnings miss despite progress By Investing.com - Investing.com South Africa
Summit Therapeutics falls on earnings miss despite progress - Investing.com
Summit Therapeutics Reports 2025 Results, Advances Ivonescimab Programs - TipRanks
Summit Therapeutics Q4 Net Loss Widens, Yearly Cash Equivalents Rise - marketscreener.com
Summit Therapeutics Inc. SEC 10-K Report - TradingView
Summit Therapeutics: Q4 Earnings Insights - Benzinga
Summit Therapeutics (NASDAQ: SMMT) posts 2025 loss but ends year with $713M cash - Stock Titan
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 - Yahoo Finance
Summit Therapeutics (SMMT) Shows Elevated Options Activity Ahead of Earnings - GuruFocus
Highs Report: Can Summit Therapeutics Inc stock outperform in a bear marketJuly 2025 Snapshot & Fast Moving Trade Plans - baoquankhu1.vn
Summit Therapeutics Set to Announce Q4 Earnings on February 23 - Intellectia AI
Summit Therapeutics (SMMT) Set to Release Q4 Earnings - GuruFocus
Preview: Summit Therapeutics's Earnings - Benzinga
Skandinaviska Enskilda Banken AB publ Has $6.99 Million Holdings in Summit Therapeutics PLC $SMMT - MarketBeat
Precision Trading with Summit Therapeutics Inc. (SMMT) Risk Zones - Stock Traders Daily
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 - BioSpace
Market Rankings: Will Summit Therapeutics Inc outperform the market in YEAR2025 Pullback Review & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough - Yahoo Finance
Summit Therapeutics (SMMT) to Release Earnings on Monday - MarketBeat
Summit Therapeutics Inc. (SMMT) Stock Analysis: A Biotech Gem with a 119.78% Upside Potential - DirectorsTalk Interviews
Is Summit Therapeutics Inc. stock near bottom after decline2025 Major Catalysts & Free Fast Entry Momentum Trade Alerts - mfd.ru
Can Summit Therapeutics Inc. stock outperform in a bear marketWeekly Profit Summary & Weekly Setup with High ROI Potential - mfd.ru
Analysis Recap: How is STSSW managing supply chain issuesJuly 2025 Review & Daily Stock Momentum Reports - baoquankhu1.vn
Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In? - Bitget
FDA accepts Summit Therapeutics’ (SMMT) BLA for ivonescimab in NSCLC with November 14 PDUFA date following positive phase III data - MSN
Summit Therapeutics Insiders Placed Bullish Bets Worth US$275.0m - 富途牛牛
Summit Therapeutics (SMMT) Is Up 6.5% After FDA Accepts Ivonescimab BLA With 2026 PDUFA Date - simplywall.st
Is Summit Therapeutics Inc. stock a good pick for beginnersMarket Activity Report & Risk Controlled Daily Plans - baoquankhu1.vn
Summit Therapeutics Enters FDA Review As Ivonescimab Trials Broaden Potential - Sahm
First Week of February 20th Options Trading For Summit Therapeutics (SMMT) - Nasdaq
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Summit Therapeutics (SMMT) Pricing Reflecting Its Recent Share Price Pullback Accurately - Yahoo Finance
Technical Reactions to SMMT Trends in Macro Strategies - Stock Traders Daily
Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
FDA Accepts Summit Therapeutics’ (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data - Yahoo Finance
Summit Therapeutics stock hits 52-week low at 14.01 USD By Investing.com - Investing.com Canada
FDA Accepts Summit Therapeutics' (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data - Finviz
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.20%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):